Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study reports that using ascorbic acid or orlistat can significantly inhibit the metabolism of testosterone esters into malodorous metabolites by axillary bacteria, suggesting potential new deodorant applications.

This study observed that new trienone compounds consistently showed higher 5alpha-reductase inhibitory activity compared to corresponding dienones across various biological models.

The researchers reported that compounds 11 to 13 derived from Westphalen-type steroids showed strong antiandrogenic activity in vivo, though their effects could not be attributed to 5α-reductase inhibition or androgen receptor binding.

This study evaluated novel steroid compounds for their ability to inhibit 5α-reductase, showing that compound 16a significantly reduced rat prostate weight more than epristeride and exhibited excellent in vitro inhibitory potency, indicating its potential as a lead candidate for further benign prostatic hyperplasia drug research.

This study found that the compound androstane-17-carboxamide 6 may serve as a lead for new drugs to treat BPH and prostate cancer by reducing the weight of androgen-dependent glands.

A new compound that could treat various androgen-related conditions was created and analyzed.

This study describes the molecular conformation and intermolecular interactions in the crystalline structure of the compound C24H31BrO4.

This study found that the synthesized compound 7b exhibited higher 5α-reductase inhibitory activity, increased solubility, and dissolution compared to finasteride, suggesting its potential as a lead compound for benign prostatic hyperplasia treatment.

A new compound was made that might help treat diseases related to male hormones.

This study found that newly synthesized steroidal trienones demonstrated stronger 5α-reductase inhibitory activity compared to dienones in various biological models, suggesting potential for developing enhanced antiandrogenic drugs.

This study found that two synthesized androst-4-ene-3-one derivatives, 6f and 6g, exhibited stronger anti-proliferative effects than common drugs on prostate cancer cell lines, with low toxicity to rat cells.

This study describes the synthesis of finasteride from 4-androstene-3,17-dione in a seven-step process with an overall yield of 18.6%.

This study found that some synthesized 17-oximino-5-androsten-3β-yl esters demonstrated stronger cytotoxicity and antiandrogenic activity against prostate cancer cells than finasteride.

The document concludes that a compound with potential for treating prostate cancer and hair loss was successfully made and its detailed structure was confirmed.

In this study, 4-substituted N-(1,1-dimethylethyl)-3-oxo-4-androstene-17.beta.-carboxamides were synthesized and evaluated in vitro as potential 5 alpha-reductase inhibitors and antiandrogens.

This study reports that newly synthesized steroidal trienones exhibit higher 5α-reductase inhibitory activity than dienones in various biological models, suggesting potential use in treating androgen-dependent diseases.

In this study, researchers developed a sensitive LC–MS–MS assay to measure 3α-androstanediol levels in rat plasma and observed that testosterone raises these levels via a 5α-reductase pathway.

This study found that two novel nonsteroidal derivatives inhibited specific enzymes in vitro and in vivo, leading to dihydrotestosterone accumulation in androgen-dependent glands, suggesting potential therapeutic use for mood improvement in the elderly.

This study found that several new pregnane derivatives, especially steroids 16 and 19, demonstrated higher antiandrogenic activity on male hamster models than the commonly used finasteride.

This review discusses alternative androgen pathways, including the "backdoor" pathway and pathways to 11-oxygenated steroids, and reports no new clinical results; the authors aim to clarify these concepts for better patient treatment.

This study reports the preparation of a key intermediate for finasteride and epristeride with a 69% overall yield from pregnenolone acetate.

This study found that bolandiol increased lean body mass and bone mineral density in castrate adult male rats, exhibiting tissue selectivity and acting through multiple receptor pathways with less potency compared to other androgens.

This study identified compounds 11d and 11k as potential dual 5α-reductase inhibitors and AR antagonists with significant anti-proliferative effects on prostate cancer cell lines, suggesting they may offer therapeutic value.

This study identified a novel class of nonsteroidal ligands that can mimic the effects of dihydrotestosterone on androgen receptors, suggesting potential therapeutic applications in male fertility and hormone replacement therapy.

This study reported that while no synthesized compounds surpassed finasteride in 5α-reductase inhibitory activity, certain 4-azasteroid-2-oximes exhibited notable inhibition.

This study found that aliphatic ester moieties in 16-formyl-17-methoxy dehydroepiandrosterone derivatives increased their potency as 5α-reductase type 2 inhibitors in vitro compared to finasteride.

This study determined the crystal structure and conformation of synthesized 17x-Acetoxy-pregn-4,6-diene-3,20-dione, revealing specific molecular interactions and structural details in an orthorhombic crystal system.

This study reported that administering finasteride reduced levels of certain neuroactive androgens in rat brains, suggesting peripheral origin for most 3α,5α-Adiol and brain synthesis for 3α,5α-A.

Researchers made two new compounds that could be used for medicine.